Retinitis pigmentosa 49

disease
On this page

Also known as CNGA1 retinitis pigmentosaretinitis pigmentosa caused by mutation in CNGA1retinitis pigmentosa type 49RP49

Summary

Retinitis pigmentosa 49 (MONDO:0013405) is a disease caused by CNGA1 (GenCC Definitive), with 2 cohort genes.

At a glance

  • Causal gene: CNGA1 (GenCC Definitive)
  • Cohort genes: 2
  • ClinVar variants: 60

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameretinitis pigmentosa 49
Mondo IDMONDO:0013405
OMIM613756
DOIDDOID:0110377
UMLSC3151059
MedGen462409
GARD0015701
Is cancer (heuristic)no

Also known as: CNGA1 retinitis pigmentosa · retinitis pigmentosa 49 · retinitis pigmentosa caused by mutation in CNGA1 · retinitis pigmentosa type 49 · RP49

Data availability: 60 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationinherited retinal dystrophyretinitis pigmentosaretinitis pigmentosa 49

Related subtypes (101): retinitis pigmentosa 6, cone-rod dystrophy 2, retinitis pigmentosa 1, retinitis pigmentosa 9, retinitis pigmentosa 10, dominant pericentral pigmentary retinopathy, late-adult onset retinitis pigmentosa, autosomal recessive pericentral pigmentary retinopathy, retinitis pigmentosa 3, retinitis pigmentosa 24, retinitis pigmentosa 23, retinitis pigmentosa 34, retinitis pigmentosa 2, retinitis pigmentosa Y-linked, retinitis pigmentosa 13, retinitis pigmentosa 12, retinitis pigmentosa 14, retinitis pigmentosa 11, retinitis pigmentosa 17, retinitis pigmentosa 18, retinitis pigmentosa 19, retinitis pigmentosa 22, retinitis pigmentosa 25, retinitis pigmentosa 28, retinitis pigmentosa 30, retinitis pigmentosa 7, retinitis pigmentosa 26, retinitis pigmentosa 32, retinitis pigmentosa 31, retinitis pigmentosa 35, retinitis pigmentosa 33, retinitis pigmentosa 36, retinitis pigmentosa 37, retinitis pigmentosa 41, retinitis pigmentosa 29, retinitis pigmentosa 46, retinitis pigmentosa 42, retinitis pigmentosa 50, retinitis pigmentosa 54, retinitis pigmentosa 51, retinitis pigmentosa 55, retinitis pigmentosa 56, retinitis pigmentosa 57, retinitis pigmentosa 58, cone-rod dystrophy 15, retinitis pigmentosa 4, retinitis pigmentosa 27, retinitis pigmentosa 47, retinitis pigmentosa 45, retinitis pigmentosa 44, retinitis pigmentosa 20, retinitis pigmentosa 40, retinitis pigmentosa 39, retinitis pigmentosa 43, retinitis pigmentosa 48, retinitis pigmentosa 59, retinitis pigmentosa 38, retinitis pigmentosa 60, retinitis pigmentosa 61, retinitis pigmentosa 62, retinitis pigmentosa 63, cone-rod dystrophy 16, retinitis pigmentosa 66, retinitis pigmentosa with or without situs inversus, retinitis pigmentosa 67, retinitis pigmentosa 68, retinitis pigmentosa 69, retinitis pigmentosa 70, retinal dystrophy and obesity, retinitis pigmentosa 71, retinitis pigmentosa 72, retinitis pigmentosa 73, retinitis pigmentosa 74, retinitis pigmentosa 75, retinitis pigmentosa 76, retinitis pigmentosa 77, retinitis pigmentosa 92, retinitis pigmentosa 93, retinitis pigmentosa 83, retinitis pigmentosa 84, retinitis pigmentosa 85, retinitis pigmentosa 86, retinitis pigmentosa 87 with choroidal involvement, retinitis pigmentosa 88, retinitis pigmentosa 90, retinitis pigmentosa 81, retinitis pigmentosa 78, retinitis pigmentosa 79, retinitis pigmentosa 80, retinitis pigmentosa 94, variable age at onset, retinitis pigmentosa 53, retinitis pigmentosa 65, retinitis pigmentosa 64, retinitis pigmentosa 95, retinitis pigmentosa 96, retinitis pigmentosa 97, retinitis pigmentosa 98, retinitis pigmentosa 99, retinitis pigmentosa 100, retinitis pigmentosa 101, retinitis pigmentosa 7, digenic

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

60 retrieved; paginated sample, class counts are floors:

16 pathogenic/likely pathogenic, 12 pathogenic, 10 uncertain significance, 10 likely pathogenic, 7 conflicting classifications of pathogenicity, 3 benign, 2 likely benign

ClinVarVariant (HGVS)GeneClassificationReview
424770NM_000087.3(CNGA1):c.[652C>T];[959C>T]Pathogeniccriteria provided, single submitter
1068762NM_001379270.1(CNGA1):c.1525G>A (p.Gly509Arg)CNGA1Pathogeniccriteria provided, multiple submitters, no conflicts
1451495NM_001379270.1(CNGA1):c.1722del (p.Asp575fs)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1454108NM_001379270.1(CNGA1):c.528del (p.Asn175_Trp176insTer)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
16930NM_001379270.1(CNGA1):c.226G>T (p.Glu76Ter)CNGA1Pathogenicno assertion criteria provided
16931NM_001379270.1(CNGA1):c.415A>T (p.Lys139Ter)CNGA1Pathogenicno assertion criteria provided
16932NM_001379270.1(CNGA1):c.947C>T (p.Ser316Phe)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
16933NM_001379270.1(CNGA1):c.1960del (p.Arg654fs)CNGA1Pathogenicno assertion criteria provided
2203541NM_001379270.1(CNGA1):c.1417del (p.Val473fs)CNGA1Pathogeniccriteria provided, single submitter
242520NM_001379270.1(CNGA1):c.640C>T (p.Arg214Ter)CNGA1Pathogeniccriteria provided, multiple submitters, no conflicts
2443933NM_001379270.1(CNGA1):c.614_615del (p.Ile205fs)CNGA1Pathogenicno assertion criteria provided
2443938NM_001379270.1(CNGA1):c.610G>A (p.Asp204Asn)CNGA1Pathogenicno assertion criteria provided
2501675NM_001379270.1(CNGA1):c.219del (p.Gln74fs)CNGA1Pathogeniccriteria provided, single submitter
3590579NM_001379270.1(CNGA1):c.1327del (p.Thr443fs)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
548707NM_001379270.1(CNGA1):c.82C>T (p.Arg28Ter)CNGA1Pathogeniccriteria provided, multiple submitters, no conflicts
802071NM_001379270.1(CNGA1):c.546-1G>CCNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
812274NM_001379270.1(CNGA1):c.1044C>A (p.Ser348Arg)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
850020NM_001379270.1(CNGA1):c.1327dup (p.Thr443fs)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
850709NM_001379270.1(CNGA1):c.530del (p.Thr177fs)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
866760NM_001379270.1(CNGA1):c.1258C>T (p.Arg420Ter)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
866975NM_001379270.1(CNGA1):c.105C>A (p.Cys35Ter)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
972420NM_001379270.1(CNGA1):c.1873C>T (p.Arg625Ter)CNGA1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1297149NM_001379270.1(CNGA1):c.234C>A (p.Tyr78Ter)LOC101927157Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
143099NM_001379270.1(CNGA1):c.179del (p.Gly60fs)LOC101927157Pathogeniccriteria provided, multiple submitters, no conflicts
2015100NM_001379270.1(CNGA1):c.527G>A (p.Trp176Ter)LOC101927157Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
225315NM_001379270.1(CNGA1):c.253del (p.Leu85fs)LOC101927157Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
236443NM_001379270.1(CNGA1):c.1528C>T (p.Arg510Ter)LOC101927157Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
866019NM_001379270.1(CNGA1):c.1743_1746del (p.Thr582fs)LOC101927157Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
1065777NM_001379270.1(CNGA1):c.1704_1705insT (p.Leu569fs)CNGA1Likely pathogeniccriteria provided, single submitter
1690446NM_001379270.1(CNGA1):c.349G>T (p.Glu117Ter)CNGA1Likely pathogeniccriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 4 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
CNGA1DefinitiveAutosomal recessiveretinitis pigmentosa 494

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
CNGA1Orphanet:791Retinitis pigmentosa
CNGB1Orphanet:791Retinitis pigmentosa

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
CNGA1HGNC:2148ENSG00000198515P29973Cyclic nucleotide-gated channel alpha-1gencc,clinvar
CNGB1HGNC:2151ENSG00000070729Q14028Cyclic nucleotide-gated channel beta-1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
CNGA1Cyclic nucleotide-gated channel alpha-1Pore-forming subunit of the rod cyclic nucleotide-gated channel.
CNGB1Cyclic nucleotide-gated channel beta-1Pore-forming subunit of the rod cyclic nucleotide-gated channel.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Ion channel2111.5×8e-05

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
CNGA1Ion channelyescNMP-bd_dom, Ion_trans_dom, RmlC-like_jellyroll
CNGB1Ion channelyescNMP-bd_dom, Ion_trans_dom, RmlC-like_jellyroll

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
amniotic fluid1
lower esophagus mucosa1
right lobe of liver1
buccal mucosa cell1
cervix squamous epithelium1
olfactory bulb1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
CNGA1182broadmarkerlower esophagus mucosa, amniotic fluid, right lobe of liver
CNGB1152tissue_specificmarkerbuccal mucosa cell, cervix squamous epithelium, olfactory bulb

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
CNGA11,181
CNGB11,133

Intra-cohort edges

ABSources
CNGA1CNGB1string_interaction

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
CNGA1P2997319
CNGB1Q1402811

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Activation of the phototransduction cascade2951.7×4e-06CNGA1, CNGB1
Inactivation, recovery and regulation of the phototransduction cascade2317.2×2e-05CNGA1, CNGB1
VxPx cargo-targeting to cilium1259.6×0.005CNGB1
Olfactory Signaling Pathway172.3×0.014CNGB1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
monoatomic cation transmembrane transport2624.1×5e-05CNGA1, CNGB1
sodium ion transport2271.8×1e-04CNGA1, CNGB1
calcium ion transport2181.2×2e-04CNGA1, CNGB1
visual perception279.5×8e-04CNGA1, CNGB1
olfactory nerve maturation12808.7×0.001CNGB1
response to odorant11404.3×0.002CNGB1
retina homeostasis1561.7×0.004CNGB1
sensory perception of chemical stimulus1561.7×0.004CNGA1
photoreceptor cell outer segment organization1526.6×0.004CNGB1
monoatomic cation transport1383.0×0.005CNGB1
detection of light stimulus involved in visual perception1324.1×0.006CNGB1
membrane depolarization1255.3×0.006CNGB1
phototransduction1247.8×0.006CNGB1
regulation of cytosolic calcium ion concentration1191.5×0.007CNGB1
photoreceptor cell maintenance1179.3×0.007CNGB1
potassium ion transport195.8×0.013CNGB1
sensory perception of smell178.0×0.015CNGB1
detection of chemical stimulus involved in sensory perception of smell162.0×0.018CNGB1
positive regulation of gene expression119.4×0.054CNGB1
G protein-coupled receptor signaling pathway118.1×0.054CNGB1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2

Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
CNGA100
CNGB100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug2CNGA1, CNGB1
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
CNGA10
CNGB10

Clinical trials & evidence

Clinical trials

Clinical trials: 0.